株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アレルギー性喘息:パイプライン分析

Allergic Asthma - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 255948
出版日 ページ情報 英文 181 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
アレルギー性喘息:パイプライン分析 Allergic Asthma - Pipeline Review, H2 2016
出版日: 2016年08月10日 ページ情報: 英文 181 Pages
概要

アレルギー性喘息は最も一般的な種類の喘息です。アレルギーは人体を細菌・ウイルスから人体を防御するという免疫系の一般的な役割の一つですが、アレルギーの症状を有している人の場合は、免疫系の一部はあまりに重々しいといえます。というのも、無害な物質(猫のふけや花粉など)もが、人体を(鼻・肺・皮膚経由で)攻撃する有害な侵入者として扱われるからです。アレルギー性喘息の場合、気道がアレルゲンに対して非常に敏感となっています。もしアレルゲンが気道に進入してくれば、免疫系が過剰反応し、気道周辺の筋肉が硬直し(気管支けいれん)、気道が炎症を起こして厚い粘液で覆われます。喘息の治療法には、抗炎症薬や気管支拡張薬の傾向接種から、吸入器によるぜんそく治療薬の服用まで、様々な方法が存在します。

当レポートでは、世界各国でのアレルギー性ぜんそく治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

アレルギー性喘息の概要

治療薬の開発

  • アレルギー性喘息向けパイプライン製品:概要
  • アレルギー性喘息向けパイプライン製品:比較分析

各企業で開発中のアレルギー性喘息治療薬

大学/研究機関で研究中のアレルギー性喘息治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

アレルギー性喘息治療薬:開発中の製品の一覧(企業別)

アレルギー性喘息治療薬:研究中の製品の一覧(大学/研究機関別)

アレルギー性喘息治療薬の開発に従事している企業

  • ALK-Abello A/S
  • Allergopharma GmbH & Co. KG
  • Amgen Inc.
  • Aquinox Pharmaceuticals Inc.
  • ASIT biotech s.a.
  • Aslan Pharmaceuticals Pte. Ltd.
  • Axikin Pharmaceuticals, Inc.
  • Baxalta Incorporated
  • Chiesi Farmaceutici SpA
  • Circassia Pharmaceuticals Plc
  • CSL Limited
  • Fountain Biopharma Inc.
  • GlaxoSmithKline Plc
  • Hydra Biosciences, Inc.
  • Infinity Pharmaceuticals, Inc.
  • Kineta, Inc.
  • Mabtech Limited
  • Marinomed Biotechnologie GmbH
  • Mycenax Biotech Inc.
  • NeoPharm Co., Ltd.
  • Oxagen Limited
  • Panacea Biotec Limited
  • Peptinnovate Limited
  • Pharmaxis Limited
  • Protectimmun GmbH
  • Stallergenes SAS
  • sterna biologicals Gmbh & Co KG
  • Swecure AB
  • The International Biotechnology Center (IBC) Generium
  • Verona Pharma Plc

アレルギー性喘息:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別
  • 薬効分類別

薬剤のプロファイル

  • AcTMP-1
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • AMG-282
  • AQX-1125
  • アラビノガラクタン
  • ASLAN-004
  • ASM-8
  • AXP-1275
  • beta-escin
  • CHF-6001
  • CSL-311
  • dalazatide
  • 喘息向けPI3キナーゼデルタ阻害薬
  • duvelisib
  • EP-67
  • FB-825
  • GNR-044
  • GSK-2245035
  • hdm-ASIT
  • HX-100
  • 乳酸連鎖球菌G121
  • Leukothera
  • OC-000459
  • OC-2417
  • omalizumab のバイオシミラー
  • OND-86
  • ペミロラストカリウム
  • ペントサン多硫酸ナトリウム
  • PIN-201601
  • RPL-554
  • S-1226
  • SB-010
  • SG-100
  • SM-301
  • アレルギー性喘息治療薬
  • アレルギー性喘息向け CaMKII阻害薬
  • 治療用標準化花粉チモシー (オオアワガエリ)アレルゲンエキス
  • 治療用標準化ダニ(コナヒョウヒダニ + ヤケヒョウヒダニ)アレルゲンエキス
  • 治療用標準化ダニ(ヤケヒョウヒダニ + コナヒョウヒダニ)アレルゲンエキス
  • SWE-01
  • tezepelumab
  • アレルギー性鼻炎・アレルギー性喘息用ワクチン
  • 草によって引き起こされる鼻炎・喘息用ワクチン

アレルギー性喘息治療薬:最新の薬剤プロファイル

アレルギー性喘息治療薬:開発が休止状態の製品

アレルギー性喘息治療薬:開発が中止された製品

アレルギー性喘息関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8350IDB

Summary

Global Markets Direct's, 'Allergic Asthma - Pipeline Review, H2 2016', provides an overview of the Allergic Asthma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Asthma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Allergic Asthma
  • The report reviews pipeline therapeutics for Allergic Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Allergic Asthma therapeutics and enlists all their major and minor projects
  • The report assesses Allergic Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Allergic Asthma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Allergic Asthma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Allergic Asthma Overview
  • Therapeutics Development
    • Pipeline Products for Allergic Asthma - Overview
    • Pipeline Products for Allergic Asthma - Comparative Analysis
  • Allergic Asthma - Therapeutics under Development by Companies
  • Allergic Asthma - Therapeutics under Investigation by Universities/Institutes
  • Allergic Asthma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Allergic Asthma - Products under Development by Companies
  • Allergic Asthma - Products under Investigation by Universities/Institutes
  • Allergic Asthma - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergopharma GmbH & Co. KG
    • Amgen Inc.
    • Aquinox Pharmaceuticals Inc.
    • ASIT biotech s.a.
    • Aslan Pharmaceuticals Pte. Ltd.
    • Chiesi Farmaceutici SpA
    • Circassia Pharmaceuticals Plc
    • CSL Limited
    • F. Hoffmann-La Roche Ltd.
    • Fountain Biopharma Inc.
    • Genentech, Inc.
    • GlaxoSmithKline Plc
    • Hydra Biosciences, Inc.
    • Infinity Pharmaceuticals, Inc.
    • KPI Therapeutics, Inc.
    • Mabtech Limited
    • Marinomed Biotechnologie GmbH
    • Mycenax Biotech Inc.
    • NeoPharm Co., Ltd.
    • Oxagen Limited
    • Panacea Biotec Limited
    • Paradigm Biopharmaceuticals Limited
    • Pharmaxis Limited
    • Protectimmun GmbH
    • Shire Plc
    • Stallergenes Greer plc
    • sterna biologicals Gmbh & Co KG
    • Swecure AB
    • Synermore Biologics Co Ltd
    • The International Biotechnology Center (IBC) Generium
    • Verona Pharma Plc
    • Xencor, Inc.
  • Allergic Asthma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AcTMP-1 - Drug Profile
    • Allergen for Allergic Asthma and Allergic Rhinitis - Drug Profile
    • AQX-1125 - Drug Profile
    • Arabinogalactan - Drug Profile
    • ASLAN-004 - Drug Profile
    • ASM-8 - Drug Profile
    • beta-escin - Drug Profile
    • CHF-6001 - Drug Profile
    • CSL-311 - Drug Profile
    • dalazatide - Drug Profile
    • Drug to Inhibit PI3 Kinase Delta for Asthma - Drug Profile
    • duvelisib - Drug Profile
    • EP-67 - Drug Profile
    • Epsi-Gam - Drug Profile
    • FB-825 - Drug Profile
    • GNR-044 - Drug Profile
    • GSK-2245035 - Drug Profile
    • hdm-ASIT - Drug Profile
    • HX-100 - Drug Profile
    • Lactococcus lactis G121 - Drug Profile
    • Leukothera - Drug Profile
    • OC-000459 - Drug Profile
    • OC-2417 - Drug Profile
    • omalizumab biosimilar - Drug Profile
    • omalizumab biosimilar - Drug Profile
    • omalizumab biosimilar - Drug Profile
    • omalizumab biosimilar - Drug Profile
    • omalizumab biosimilar - Drug Profile
    • OND-86 - Drug Profile
    • pemirolast potassium - Drug Profile
    • pentosan polysulfate sodium - Drug Profile
    • RG-6149 - Drug Profile
    • RG-7990 - Drug Profile
    • RPL-554 - Drug Profile
    • SB-010 - Drug Profile
    • SG-100 - Drug Profile
    • SM-301 - Drug Profile
    • Small Molecule for Allergic Asthma - Drug Profile
    • Small Molecules for Allergic Asthma - Drug Profile
    • Small Molecules to Inhibit 5-Lipoxygenase for Allergic Asthma - Drug Profile
    • Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile
    • standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile
    • standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
    • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
    • SWE-01 - Drug Profile
    • Synthetic Peptides for Allergic Asthma and Rheumatoid Arthritis - Drug Profile
    • tezepelumab - Drug Profile
    • Vaccine for Allergic Asthma - Drug Profile
    • Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile
    • XmAb-7195 - Drug Profile
  • Allergic Asthma - Dormant Projects
  • Allergic Asthma - Discontinued Products
  • Allergic Asthma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Allergic Asthma, H2 2016
  • Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Allergic Asthma - Pipeline by ALK-Abello A/S, H2 2016
  • Allergic Asthma - Pipeline by Allergopharma GmbH & Co. KG, H2 2016
  • Allergic Asthma - Pipeline by Amgen Inc., H2 2016
  • Allergic Asthma - Pipeline by Aquinox Pharmaceuticals Inc., H2 2016
  • Allergic Asthma - Pipeline by ASIT biotech s.a., H2 2016
  • Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2016
  • Allergic Asthma - Pipeline by Chiesi Farmaceutici SpA, H2 2016
  • Allergic Asthma - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
  • Allergic Asthma - Pipeline by CSL Limited, H2 2016
  • Allergic Asthma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Allergic Asthma - Pipeline by Fountain Biopharma Inc., H2 2016
  • Allergic Asthma - Pipeline by Genentech, Inc., H2 2016
  • Allergic Asthma - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Allergic Asthma - Pipeline by Hydra Biosciences, Inc., H2 2016
  • Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016
  • Allergic Asthma - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Allergic Asthma - Pipeline by Mabtech Limited, H2 2016
  • Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H2 2016
  • Allergic Asthma - Pipeline by Mycenax Biotech Inc., H2 2016
  • Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H2 2016
  • Allergic Asthma - Pipeline by Oxagen Limited, H2 2016
  • Allergic Asthma - Pipeline by Panacea Biotec Limited, H2 2016
  • Allergic Asthma - Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016
  • Allergic Asthma - Pipeline by Pharmaxis Limited, H2 2016
  • Allergic Asthma - Pipeline by Protectimmun GmbH, H2 2016
  • Allergic Asthma - Pipeline by Shire Plc, H2 2016
  • Allergic Asthma - Pipeline by Stallergenes Greer plc, H2 2016
  • Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016
  • Allergic Asthma - Pipeline by Swecure AB, H2 2016
  • Allergic Asthma - Pipeline by Synermore Biologics Co Ltd, H2 2016
  • Allergic Asthma - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
  • Allergic Asthma - Pipeline by Verona Pharma Plc, H2 2016
  • Allergic Asthma - Pipeline by Xencor, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Allergic Asthma - Dormant Projects, H2 2016
  • Allergic Asthma - Dormant Projects (Contd..1), H2 2016
  • Allergic Asthma - Dormant Projects (Contd..2), H2 2016
  • Allergic Asthma - Dormant Projects (Contd..3), H2 2016
  • Allergic Asthma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Allergic Asthma, H2 2016
  • Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top